Merck KGaA (FRA:MRK) received a €102.00 ($118.60) price objective from research analysts at Independent Research in a note issued to investors on Friday, Borsen Zeitung reports. The firm currently has a “neutral” rating on the healthcare company’s stock. Independent Research’s price target suggests a potential upside of 7.53% from the stock’s previous close.
Several other research analysts have also issued reports on MRK. Kepler Capital Markets set a €108.00 ($125.58) price target on shares of Merck KGaA and gave the stock a “buy” rating in a research report on Monday, June 17th. Morgan Stanley set a €96.00 ($111.63) price target on shares of Merck KGaA and gave the stock a “neutral” rating in a research report on Tuesday, June 18th. UBS Group set a €99.00 ($115.12) price target on shares of Merck KGaA and gave the stock a “neutral” rating in a research report on Thursday. Barclays set a €82.00 ($95.35) price target on shares of Merck KGaA and gave the stock a “sell” rating in a research report on Monday, May 27th. Finally, Nord/LB set a €94.00 ($109.30) price target on shares of Merck KGaA and gave the stock a “neutral” rating in a research report on Friday. One analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of €100.05 ($116.34).
Merck KGaA stock traded up €0.30 ($0.35) during mid-day trading on Friday, hitting €94.86 ($110.30). The company’s stock had a trading volume of 484,060 shares. Merck KGaA has a twelve month low of €76.60 ($89.07) and a twelve month high of €115.00 ($133.72). The firm’s fifty day simple moving average is €93.46.
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Recommended Story: Quiet Period Expirations
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.